Premium
Glycaemic status and cardiovascular disease in type 2 diabetes mellitus: re‐visiting glycated haemoglobin targets for cardiovascular disease prevention
Author(s) -
Golden Sherita H.,
Selvin Elizabeth,
Cunningham Kayla E.
Publication year - 2007
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/j.1463-1326.2006.00673.x
Subject(s) - medicine , disease , diabetes mellitus , type 2 diabetes , epidemiology , clinical trial , type 2 diabetes mellitus , macrovascular disease , risk factor , intensive care medicine , glycated haemoglobin , glycated hemoglobin , endocrinology
Cardiovascular disease (CVD) is the leading cause of death among people with type 2 diabetes. Recent attention has focused on chronic hyperglycaemia as an additional risk factor in people with diabetes since their excess CVD risk is not entirely explained by traditional cardiovascular risk factors. Clinical trials of intensive glucose control to reduce CVD events have been equivocal, but recent epidemiological studies have shown that HbAlc, a measure of chronic hyperglycaemia, predicts incident cardiovascular events. This review, which focuses on type 2 diabetes, summarizes (i) the epidemiological literature examining the relation between glycaemic status, as assessed by glycated haemoglobin (HbAlc) and CVD, (ii) the controversy regarding treatment goals for HbAlc in terms of preventing microvascular disease vs. macrovascular disease and (iii) on‐going clinical trials of intensive glycaemic control for CVD prevention.